Biomea Fusion, Inc. - BMEA STOCK NEWS

Biomea Fusion (NASDAQ: BMEA) announced new preclinical data for the combination of icovamenib with semaglutide. The study demonstrated significant improvements compared to semaglutide alone, including an additional 11.5% body weight reduction and a 43% increase in lean muscle mass.

The combination therapy showed approximately doubled C-peptide production per unit of glucose compared to semaglutide alone, resulting in a 60% improved reduction of fasting blood glucose. Previous ex vivo human islet experiments showed icovamenib enhanced GLP-1-based therapies' activity, increasing insulin secretion.

Additionally, topline data from the COVALENT-111 study revealed that 12 weeks of daily icovamenib in patients uncontrolled on GLP-1-based therapy (n=10) achieved an HbA1c reduction of 0.84% at week 26. Further data will be presented at the upcoming J.P. Morgan Conference in January 2025.

Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.

Thomas Butler, CEO and Board Chairman, will deliver a presentation on Wednesday, January 15, 2025, at 1:30 PM PT / 4:30 PM ET. The company's management team will also conduct one-on-one meetings throughout the conference, which runs from January 13 to January 16.

Interested parties can access a live audio webcast of the presentation through the company's investor relations website at investors.biomeafusion.com/news-events/events, with a replay available after the live presentation.

Biomea Fusion (BMEA) announced positive topline results from its Phase II COVALENT-111 study evaluating icovamenib in type 2 diabetes patients. The study met its primary endpoint, showing statistically significant HbA1c reductions across all major categories. The most significant results were observed in insulin-deficient patients, with a placebo-adjusted mean reduction of 1.47% in HbA1c at Week 26 in the severe insulin-deficient diabetes (SIDD) group.

The study enrolled 225 patients, with 168 completing the per-protocol analysis. The optimal dosing was identified as 100mg once daily for 12 weeks, showing a mean HbA1c reduction of 0.5%. Notably, the drug demonstrated efficacy in patients who failed GLP-1 based therapy, achieving an HbA1c reduction of 0.84%. The treatment was well-tolerated with no serious adverse events or discontinuations due to adverse events.

Biomea Fusion (BMEA) has announced a conference call and webcast scheduled for Tuesday, December 17, 2024, at 8:00 am EST to present topline results from COVALENT-111, their Phase II trial of icovamenib in patients with type 2 diabetes. The company, which focuses on developing oral covalent small molecules for diabetes, obesity, and genetically defined cancers, will make the webcast available to registered attendees through their investor relations website, with a replay available afterward.

Biomea Fusion (NASDAQ: BMEA) presented significant preclinical findings for icovamenib, their investigational covalent menin inhibitor, at the 22nd WCIRDC. The research demonstrated that icovamenib enhanced beta cell function and improved responsiveness to GLP-1-based therapies in human islets. Key findings showed increased expression of GLP-1 receptors and intracellular insulin, with synergistic effects when combined with therapies like semaglutide and tirzepatide.

The data suggests that icovamenib's ability to increase beta cell mass could potentially allow for lower doses of GLP-1-based therapies while maintaining glycemic targets, potentially reducing side effects. Clinical case studies indicated that short-term icovamenib treatment was well-tolerated with no significant adverse events or hypoglycemia reported.

Biomea Fusion (BMEA) announced preliminary data from its Phase I COVALENT-103 study of BMF-500, a covalent FLT3 inhibitor for relapsed or refractory acute leukemia. The study enrolled 20 patients, including 13 with confirmed FLT3-mutations, who had previously failed gilteritinib treatment.

Key findings include: no dose-limiting toxicities across all dose levels, favorable safety profile, and demonstrated FLT3 inhibition with bone marrow penetration. Clinical activity was observed with one complete response with incomplete hematologic recovery (CRi) at 100mg twice daily dosing, and bone marrow blast reductions in 5 of 6 evaluable FLT3 mutated patients.

The highlighted case study showed a CRi in a 61-year-old patient with R/R AML who had failed four prior treatment regimens.

Biomea Fusion (NASDAQ: BMEA) has announced a conference call and webcast scheduled for December 9, 2024, at 4:30 pm EST. The presentation will reveal initial clinical data from the Phase I COVALENT-103 study of BMF-500, their investigational covalent FLT3 inhibitor, in patients with relapsed or refractory acute leukemia.

BMF-500 was developed using Biomea's proprietary FUSION™ System. The webcast will be accessible to registered attendees through the company's investor relations website, with a replay available after the event.

Biomea Fusion announced that its compensation committee granted stock options to one new employee on December 2, 2024. The grant includes options to purchase 30,000 shares of common stock, which will vest quarterly over four years at a rate of 1/16. The grant was made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, and serves as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Biomea Fusion presented new analysis from COVALENT-111 trial at ATTD-ASIA 2024, showing promising results for icovamenib in Type 2 Diabetes (T2D) treatment. The study revealed that insulin-deficient patients (approximately 50% of the population) showed a greater mean HbA1c reduction (-1.23% vs -0.48%) compared to insulin-resistant patients at Week 26, following 4 weeks of dosing.

Notable case studies included a 29-year-old patient achieving a 2.5% HbA1c reduction and a 45-year-old patient showing a 1.1% reduction, both with significant improvements in HOMA-B and C-peptide levels. The company expects topline results from the Phase IIb expansion portion, involving over 200 T2D patients, in December.